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Introduction
The vascular endothelial growth factor (VEGF) and PDGF fam-
ily members are closely related. In Drosophila melanogaster 
three PDGF/VEGF-like factors (PVFs) have been identifi  ed 
that function through a single receptor to mediate guidance of 
cell migration (Duchek et al., 2001; Cho et al., 2002). A PVF 
identifi  ed in Caenorhabditis elegans was shown to bind the 
  human VEGF receptors (VEGFRs) VEGFR1 and VEGFR2, 
which mediated angiogenesis (Tarsitano et al., 2006). Sequence 
analysis of VEGF, PDGF, and PVF members predicts that 
VEGF and PDGF evolved from a common ancestor (Holmes 
and Zachary, 2005). Both VEGF and PDGF belong to the cystine-
knot superfamily of signaling molecules, which is characterized 
by having a cystine-knot structure formed by eight cysteine 
  residues (Vitt et al., 2001).
The most abundant and active member of the VEGF 
family is VEGF-A (Holmes and Zachary, 2005; Yamazaki and 
Morita, 2006), which undergoes alternative splicing to produce 
several different isoforms. The predominant human isoforms 
are VEGF-A165 and -A121, which lacks a heparin-binding 
domain (Neufeld et al., 1999). Three VEGFR tyrosine kinases 
(RTKs; VEGFR1-3) that form homodimers on ligand binding 
have been identifi  ed (Holmes and Zachary, 2005; Yamazaki 
and Morita, 2006). VEGF-A binds to VEGFR1 and VEGFR2, 
but not VEGFR3, but most signal transduction is mediated 
by VEGFR2 (Zachary and Gliki, 2001; Cross et al., 2003). 
All three VEGFRs are structurally related to the PDGF class III 
RTK subfamily, which are all characterized by seven extra-
cellular immunoglobulin-like domains with an intracellular 
tyrosine kinase domain interrupted by a noncatalytic region 
(Petrova et al., 1999). These and other structural similarities 
between VEGFRs and PDGF receptors (PDGFRs) suggest a close 
evolutionary relationship (Kondo et al., 1998).
The PDGF family consists of four different PDGF chains 
(A–D), which assemble into functional homodimers or a PDGF-
AB heterodimer, and two PDGFR tyrosine kinases (α and β), 
which form a homodimer or heterodimer on ligand binding 
(Betsholtz, 2004; Fredriksson et al., 2004). PDGF-AA binds 
only PDGFRα, whereas PDGF-BB binds both homodimer and 
heterodimer PDGFRs. The less abundant PDGF-CC and -DD 
bind to PDGFRα and PDGFRβ homodimers, respectively, with 
both binding to the PDGFRαβ heterodimer. PDGF-C and -D 
have a novel N-terminal CUB domain and are structurally more 
similar to the VEGF family than the PDGFs (Fredriksson et al., 
2004; Reigstad et al., 2005).
VEGF-A and PDGF-BB are both critical factors in promot-
ing the recruitment and proliferation of vascular cells (Benjamin 
et al., 1998; Yancopoulos et al., 2000). Adult bone marrow–
  derived mesenchymal stem cells (MSCs), which can differenti-
ate to vascular cells (Galmiche et al., 1993; Kashiwakura et al., 
2003; Ball et al., 2004), may be recruited during angiogenesis 
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and to sites of vascular injury (Shimizu et al., 2001; Abedin 
et al., 2004). Although PDGF isoforms induce human MSC 
  migration (Fiedler et al., 2004), less is known of VEGF-A–
  mediated effects, with several studies reporting no VEGFR ex-
pression in MSCs (Furumatsu et al., 2003; Kim et al., 2005). 
In this investigation, we examined the role of VEGF-A in regu-
lating MSC migration and proliferation.
We report that VEGF-A can directly signal through 
PDGFR, which represents a novel VEGF-A/PDGFR signaling 
mechanism. This study provides important new insights into 
how VEGF signaling regulates MSC recruitment and prolifera-
tion during tissue regeneration and disease.
Results
MSC recruitment and proliferation by vascular growth factors 
are critical events during blood vessel growth, repair, and dis-
ease. In this study, we examined the chemotactic and mitogenic 
effects of VEGF-A on MSCs.
VEGF-A–induced MSC migration 
and proliferation
Boyden chamber migration assays were used to analyze the 
chemotactic effects of 10 ng/ml VEGF-A on MSC migration. 
10 ng/ml PDGF was used as a positive control. Both VEGF-A165 
and -A121 isoforms signifi  cantly increased MSC migration by 
 2.2-fold above basal levels (Fig. 1 A). In comparison, both 
PDGF-AA and -BB isoforms resulted in an  3.3-fold increase 
in MSC migration (Fig. 1 A). VEGF-A–induced MSC migra-
tion was dose dependent, with both isoforms producing maxi-
mal stimulation at 10 ng/ml VEGF-A (unpublished data).
In addition to inducing MSC migration, VEGF-A also 
stimulated MSC proliferation. Both VEGF-A165 and -A121 iso-
forms (10 ng/ml) resulted in enhanced MSC proliferation by 
day 2 (Fig. 1 B), which signifi  cantly increased up to day 5. In 
comparison, PDGF-AA and -BB isoforms (10 ng/ml) signifi  -
cantly enhanced proliferation by day 1. Both VEGF-A and 
PDGF isoforms had a similar effect on MSC proliferation by 
day 5 (Fig. 1 B).
MSCs do not express VEGFRs
To identify which VEGFRs were expressed on MSCs, RT-PCR 
analysis was performed using total RNA isolated from MSCs, 
with human umbilical vein endothelial cells (HUVECs) and 
human dermal fi  broblast (HDF) cells used as VEGFR-positive 
and -negative control cells, respectively. Using two different sets 
of primer pairs for each VEGFR, no VEGFR1, VEGFR2, or 
VEGFR3 transcripts were identifi  ed in MSC- or HDF-derived 
Figure 1.  Exposure to VEGF-A increased MSC migration 
and proliferation. (A) MSC migration was examined in 
serum-free conditions after a 5-h exposure to a growth 
factor; 10 ng/ml VEGF-A165, VEGF-A121, PDGF-AA, or 
PDGF-BB in the lower half of a Boyden chamber. Basal 
represents growth factor–independent migration. Images 
below each bar graph are representative of migratory 
cells/ﬁ  eld (using a 10× objective lens) on the membrane 
underside. Data shown are the mean number of migra-
tory cells ± the SD determined from 10 random ﬁ  elds 
from each of four independent experiments. *, P < 0.001, 
compared with basal migration. (B) MSC proliferation 
was determined over a 5-d period after incubation with 
growth medium supplemented with fresh growth factor; 
10 ng/ml VEGF-A165, VEGF-A121, PDGF-AA, or PDGF-BB 
every 24 h. Basal represents proliferation independent of 
supplemented growth factors. Data shown are the mean 
cell number ± the SD determined from triplicate assays 
from each of two independent experiments. *, P < 0.001; 
#, P < 0.005 compared with the respective basal 
cell proliferation.VEGF CAN SIGNAL THROUGH PDGF RECEPTORS • BALL ET AL. 491
RNA (Fig. 2 A). In comparison, both VEGFR1 and VEGFR2 
transcripts were readily detected in HUVECs. Although all 
three cell types expressed VEGF-A, MSCs had the highest 
abundance, but only a low level was determined in HUVECs. In 
addition, all three cell types also expressed neuropilin (NP)-1 
and -2 coreceptor transcripts, but HDFs expressed only a trace 
amount of NP-2 (Fig. 2 A). Single-color fl  ow-cytometry, using 
either phycoerythrin (PE)-conjugated antibodies (Fig. 2 B) or 
FITC-labeled antibodies (unpublished data), both demonstrated 
that MSCs and HDFs expressed no detectable cell surface 
VEGFR1, VEGFR2, or VEGFR3 protein. In comparison, 
HUVECs were shown to express abundant cell surface VEGFR1 
and VEGFR2 (Fig. 2 B). After the end of migration assays, 
when MSCs had been exposed to either 10 ng/ml VEGF-A165 
or -A121 for 5 h, both RT-PCR and fl  ow cytometry analysis 
again demonstrated no detectable VEGFR1-3 expression 
Figure 2.  MSCs expressed no VEGFRs. The expression of VEGFR mRNA transcripts was examined by semiquantitative RT-PCR analysis and cell surface 
protein expression by single-color ﬂ  ow cytometry, using human MSCs, HUVECs as a VEGFR-positive control cell, and HDF as a VEGFR-negative control 
cell. (A) RNA isolated from MSCs, HUVECs, and HDFs were used to amplify VEGFR1-3, VEGF-A, NP-1, and NP-2 transcripts, with GAPDH as a control, 
and then resolved by agarose gel. Lane 1, VEGFR1 (99 bp); lane 2, VEGFR2 (81 bp); lane 3, VEGFR3 (87 bp); lane 4, VEGF-A (98 bp); lane 5, GAPDH 
(71 bp); lane 6, NP-1 (77 bp); lane 7, NP-2 (83 bp). Data are representative of six independent experiments, with two different pairs of primers for 
VEGFR1-3 used. (B) Flow cytometry using PE-conjugated antibodies. Analysis of VEGFR1-3 is represented by VEGFR1-, VEGFR2-, and VEGFR3-PE expres-
sion, respectively, with IgG1-PE expression as a control. A representative example of three independent experiments is shown.JCB • VOLUME 177 • NUMBER 3 • 2007  492
  (unpublished data). Human MSCs from fi  ve different individ-
uals were all VEGFR-negative, refl  ecting the lack of VEGFRs 
in these cells.
PDGFR𝗂 and PDGFR𝗃 are essential 
for VEGF-A–induced MSC migration 
and proliferation
To confi  rm that VEGF-A–induced MSC migration was not 
mediated by VEGFR signaling, MSCs or HUVECs used 
as VEGFR-positive cells were pretreated with either specifi  c 
VEGFR1 or VEGFR2 neutralization antibodies or a specifi  c 
VEGFR2 tyrosine kinase inhibitor (VEGFR2-TK) before VEGF-
A–induced migration. As a negative control, both cell types 
were also pretreated with a specifi  c PDGFR tyrosine kinase 
inhibitor (PDGFR-TK). Pretreatment with either VEGFR1 
or VEGFR2 neutralization antibodies or with VEGFR2-TK 
inhibition, all significantly decreased VEGF-A165–induced 
HUVEC migration (Fig. 3 A). In comparison, cell surface anti-
body neutralization of either VEGFR1 or VEGFR2, or intra-
cellular VEGFR2-TK inhibition, had no substantial effect on 
VEGF-A165–induced MSC migration (Fig. 3 A). Although 
pretreatment with PDGFR-TK had no substantial effect on 
VEGF-A165–induced HUVEC migration (Fig. 3 A), surpris-
ingly, VEGF-A165–induced MSC migration was signifi  cantly 
reduced (Fig. 3 A), indicating PDGFR involvement in VEGF-A–
induced MSC migration. Similar results were obtained using 
isoform VEGF-A121 (unpublished data).
We next investigated the relationship between PDGFRs 
and VEGF-A–stimulated MSC migration by blocking cell 
surface PDGFRα or PDGFRβ, using selective neutralization 
antibodies. MSCs, or HUVECs used as a VEGFR-positive 
cell, were pretreated with either a PDGFRα- or PDGFRβ-specifi  c 
neutralization antibody before VEGF-A–induced migration. 
Blocking either cell surface PDGFRα or PDGFRβ signifi  -
cantly inhibited VEGF-A165– or VEGF-A121–induced MSC 
migration (Fig. 3 A and not depicted), with PDGFRα neutral-
ization resulting in greater inhibition of VEGF-A stimulation. 
In comparison, neither PDGFRα nor PDGFRβ neutralization 
Figure 3. Inhibiting  PDGFR𝗂 or PDGFR𝗃 
  attenuated VEGF-A–induced MSC migration. 
(A) MSCs, or HUVECs used as a VEGFR-
positive cell, were pretreated with either 10 
μg/ml anti-VEGFR1 or -VEGFR2 neutralization 
antibodies, 100 nM VEGFR2 tyrosine kinase 
inhibitor (VEGFR2-TK), 2 μM PDGFR tyrosine 
kinase inhibitor (PDGFR-TK), and 10 μg/ml 
anti-PDGFRα or -PDGFRβ neutralization anti-
bodies; then, either 10 ng/ml VEGF-A165 
or 10 ng/ml VEGF-A121 (not depicted) were 
added to the lower half of a Boyden chamber 
for 5 h. No inhibition represents control VEGF-
A–induced migration. (B) As a control, MSCs 
were pretreated with either 10 μg/ml anti-
PDGFRα or -PDGFRβ neutralization antibodies, 
and then 10 ng/ml PDGF-BB was added to the 
lower half of a Boyden chamber for 5 h. No 
inhibition represents control PDGF-BB–induced 
migration. (C) MSCs were transfected with ei-
ther 3 μg siRNA PDGFRα, siRNA PDGFRβ, or 
scrambled siRNA used as a control. Trans-
fected MSCs in serum-free conditions were 
either unstimulated as a control, or exposed to 
10 ng/ml VEGF-A165 in the lower half of a Boy-
den chamber for 5 h. Images below each bar 
graph are representative of migratory cells/ﬁ  eld 
(using a 10× objective lens) on the membrane 
underside. Data shown are the mean number 
of migratory cells ± the SD, which were deter-
mined from 10 random ﬁ  elds from each of four 
(A) or two (B and C) independent experiments. 
*, P < 0.001, compared with the respective 
uninhibited VEGF-A165–stimulated cells.VEGF CAN SIGNAL THROUGH PDGF RECEPTORS • BALL ET AL. 493
had any substantial impact on VEGF-A165–induced HUVEC 
migration (Fig. 3 A) or PDGF-BB–induced MSC migration 
(Fig. 3 B). Thus, functional cell surface PDGFRα and 
PDGFRβ are both crucial determinants in mediating VEGF-A–
induced MSC migration.
To further demonstrate that both PDGFRα and PDGFRβ 
are crucial receptors in directing VEGF-A–induced MSC 
migration, we used specifi   c validated siRNA PDGFRα and 
PDGFRβ nucleotides to knockdown the respective transcripts. 
VEGF-A165 stimulation of MSCs transfected with scrambled 
siRNA as a control resulted in an  2.5-fold increase in migra-
tion above unstimulated scrambled siRNA control levels (Fig. 
3 C). However, VEGF-A165 stimulation of MSCs transfected 
with either siRNA PDGFRα or PDGFRβ both resulted in a 
signifi  cant inhibition of migration (Fig. 3 C). Thus, PDGFRα 
or PDGFRβ inhibition by siRNA knockdown or cell surface 
neutralization (Fig. 3 A) both effectively inhibited VEGF-A165–
 induced  migration.
Having demonstrated that 5-d exposure to VEGF-A165 sig-
nifi  cantly enhanced MSC proliferation (Fig. 1 B), we stimulated 
MSCs with VEGF-A165 in the presence of either PDGFRα or 
PDGFRβ neutralization antibodies, and then examined the ef-
fects on proliferation at day 5. Blocking cell surface PDGFRα 
or PDGFRβ signifi  cantly inhibited VEGF-A165–induced MSC 
proliferation (Fig. S1, available at http://www.jcb.org/cgi/content/
full/jcb.200608093/DC1). In comparison, neither VEGFR1 
nor VEGFR2 neutralization antibodies had any substantial 
 impact  on  VEGF-A165–induced MSC proliferation (Fig. S1). 
Thus, functional cell surface PDGFRα and PDGFRβ are both 
essential in mediating VEGF-A–induced MSC migration 
and proliferation.
VEGF-A–induced HDF migration was also 
mediated by PDGFR𝗂 and PDGFR𝗃
Having confi  rmed that HDFs did not express VEGFR transcripts 
or cell surface receptors (Fig. 2), we wished to establish whether 
Figure 4.  VEGF-A–induced HDF migration was PDGFR𝗂 and PDGFR𝗃 dependent. (A) The expression of cell surface PDGFRs on HDFs were determined by 
single-color ﬂ  ow cytometry. Analysis of PDGFRα and PDGFRβ was performed using anti–human PE-conjugated antibodies, using an IgG1-PE antibody as a 
control. (B) The effects of VEGF-A on HDF migration and the involvement of PDGFRs were examined using Boyden chamber migration assays. HDF migra-
tion was evaluated in serum-free conditions after 5-h exposure to growth factor; 20 ng/ml VEGF-A165, VEGF-A121, PDGF-AA, or PDGF-BB in the lower half 
of a Boyden chamber. Basal represents growth factor–independent migration. (C) HDFs were pretreated with either 10 μg/ml anti-PDGFRα or -PDGFRβ 
neutralization antibodies, before adding 20 ng/ml VEGF-A165 to the lower half of a Boyden chamber for 5 h. No inhibition represents control VEGF-A165–
  induced migration. (D) HDFs were transfected with either 3 μg siRNA PDGFRα, siRNA PDGFRβ, or scrambled siRNA used as a control. Transfected HDFs 
in serum-free conditions were either unstimulated as a control, or exposed to 20 ng/ml VEGF-A165 in the lower half of a Boyden chamber for 5 h. Images 
below each bar graph are representative of migratory cells/ﬁ  eld (using a 10× objective lens) on the underside of the membrane. Data shown are the mean 
number of migratory cells ± the SD determined from 10 random ﬁ  elds from each of three independent experiments. *, P < 0.001, compared with the 
  respective uninhibited VEGF-A165 or PDGF-stimulated cells.JCB • VOLUME 177 • NUMBER 3 • 2007  494
VEGF-A could also induce HDF migration by a PDGFR-
dependent mechanism. Flow cytometry demonstrated that HDFs 
expressed abundant cell surface PDGFRα and PDGFRβ (Fig. 
4 A). Boyden chamber migration analysis demonstrated that both 
VEGF-A165 and -A121 isoforms signifi  cantly induced a similar 
level of HDF migration as either PDGF-AA or -BB; the level of 
migration was  2.0-fold above basal levels (Fig. 4 B). Selec-
tively inhibiting either PDGFRα or PDGFRβ using specifi  c cell 
surface neutralization antibodies before growth factor exposure 
signifi  cantly inhibited VEGF-A165– and -A121–induced HDF 
migration (Fig. 4 C and not depicted). The involvement of both 
PDGFRα and PDGFRβ in mediating VEGF-A165–induced HDF 
migration was further demonstrated by siRNA PDGFR knock-
down. VEGF-A165 stimulation of HDFs transfected with scram-
bled siRNA as a control produced a 2.2-fold increase in 
migration above unstimulated control level, whereas siRNA 
knockdown of either PDGFRα or PDGFRβ resulted in a sig-
nifi  cant inhibition of VEGF-A165–induced HDF migration (Fig. 
4 D). Thus, both VEGF-A165–induced MSC and HDF migration 
were dependent on a PDGFR-mediated mechanism.
VEGF-A165–induced PDGFR𝗂 and PDGFR𝗃 
tyrosine phosphorylation
Ligand binding to a PDGFR induces receptor dimerization, 
which is a prerequisite for autophosphorylation of specific 
tyrosine residues and initiation of signal transduction (Heldin 
and Westermark, 1999). Having clearly demonstrated the 
involvement of both PDGFRs in VEGF-A–induced MSC and 
HDF migration, we next examined whether VEGF-A165 re-
sulted in PDGFR tyrosine autophosphorylation by using a hu-
man phospho-RTK array containing 42 different specifi  c RTK 
antibodies. This approach not only allowed the simultaneous 
relative quantitation of both PDGFR tyrosine phosphoryla-
tion levels, but also detected tyrosine phosphorylation of 40 
other RTKs, including all three VEGFRs, in the same isolated 
cell lysate. Furthermore, this approach was an effective means 
to validate the effi   ciency of siRNA knockdown to inhibit 
PDGFR signaling.
RTK array analysis demonstrated that unstimulated MSC 
lysate resulted in all 42 different RTKs having a very low basal 
level of tyrosine phosphorylation (Fig. 5 A).
Figure 5.  VEGF-A stimulated both PDGFR𝗂 and PDGFR𝗃 
tyrosine phosphorylation. Human phospho-RTK arrays 
were used to examine VEGF-A–induced RTK phosphoryla-
tion levels in MSC lysate samples. Arrays contain phos-
photyrosine-positive control spots in each corner, having 
coordinates (A1, A2), (A23, A24), (F1, F2), (F23, F24), 
which were assigned a pixel density value of 100, which 
was used to normalize positive RTK spot pixel density val-
ues. Relevant RTK duplicate spot coordinates: PDGFRα = 
(C7, C8), PDGFRβ = (C9, C10), VEGFR1 = (D9, D10), 
VEGFR2 = (D11, D12), VEGFR3 = (D13, D14), EGFR = 
(B1, B2), FGFR3 = (B13, B14), Axl = (B21, B22), EphA7 = 
(E3, E4). (A) RTK array analysis of control MSC lysate, 
not stimulated with exogenous growth factor (basal). 
(B) RTK array analysis of lysates from MSCs transfected 
with 3 μg scrambled siRNA as a control, siRNA PDGFRα 
or siRNA PDGFRβ, stimulated using 20 ng/ml VEGF-A165 
in serum-free conditions for 10 min at 37°C. Each array 
was identically exposed to detection reagents and ﬁ  lm. 
(C) Bar graph representing data from arrays (A and B). 
Mean pixel density ± the SD of duplicate spots, normal-
ized against duplicate phosphotyrosine-positive control 
spots = 100. A representative example of two indepen-
dent experiments is shown for each array analysis. *, P < 
0.001 compared with the respective VEGF-A165–stimulated 
scrambled siRNA control.VEGF CAN SIGNAL THROUGH PDGF RECEPTORS • BALL ET AL. 495
When MSCs transfected with scrambled RNA (control) 
were stimulated with VEGF-A165 for 10 min, RTK array analy-
sis demonstrated that the cell lysate contained distinct PDGFRα 
and PDGFRβ tyrosine phosphorylation (densitometry values = 
37 ± 3 and 49 ± 3, respectively; Fig. 5 B). Thus, VEGF-A165 
specifi  cally activates both PDGFRα and PDGFRβ RTK signal-
ing activities. Importantly, no VEGFR1-3 receptor tyrosine phos-
phorylation was detected, further verifying that VEGF-A 
stimulation of MSCs is not mediated by VEGFRs (Fig. 5 B).
After siRNA PDGFRα or PDGFRβ knockdown, followed 
by VEGF-A165 stimulation, array analysis demonstrated that the 
cell lysate contained a signifi  cant decrease in the tyrosine phos-
phorylation state of PDGFRα (densitometry value = 7 ± 1) and 
PDGFRβ (densitometry value = 12 ± 1), respectively (Fig. 5, 
B and C). Thus, VEGF-A165 stimulated dimerization and acti-
vation of both PDGFRα and PDGFRβ receptors. Interestingly, 
VEGF-A165 stimulation also induced tyrosine phosphorylation 
of other RTKs, notably EGFR, EphA7, and Axl (Fig. 5 B).
Stimulation with PDGF-BB, which is the normal ligand for 
both PDGFRα and PDGFRβ, was also examined. This allowed 
a comparison with the level of VEGF-A165–stimulated PDGFRα 
and PDGFRβ tyrosine phosphorylation, and also further vali-
dated the siRNA PDGFR knockdown effi  ciency and specifi  city. 
After siRNA PDGFRα or PDGFRβ knockdown, followed by 
PDGF-BB stimulation, the results demonstrated that the respec-
tive siRNA PDGFRα and PDGFRβ knockdowns were both 
effective and specifi  c (Fig. 6 A), validating their corresponding 
effects in inhibiting VEGF-A165–induced MSC and HDF migra-
tion (Fig. 3 C and Fig. 4 D). Using MSCs transfected with 
scrambled siRNA, followed by PDGF-BB stimulation, array 
analysis of the cell lysate demonstrated both PDGFRα and 
PDGFRβ tyrosine phosphorylation (densitometry values = 
81 ± 6 and 294 ± 12, respectively; Fig. 6 A). Thus, whereas 
20 ng/ml VEGF-A165 induced similar levels of PDGFRα and 
PDGFRβ tyrosine phosphorylation (Fig. 5 B), in comparison, 
20 ng/ml PDGF-BB induced 2.2- ±  0.1-fold and 6.0- ± 
0.2-fold higher levels of PDGFRα and PDGFRβ tyrosine phos-
phorylation, respectively (Fig. 6 B).
Immunoprecipitation analysis also demonstrated that 
VEGF-A165 increased PDGFRα and PDGFRβ tyrosine phos-
phorylation levels, compared with the unstimulated basal state 
(Fig. 6 C). Although 20 ng/ml PDGF-BB induced a similar level 
Figure 6.  VEGF-A–induced PDGFR tyrosine phosphory-
lation was comparable to PDGF-BB–induced PDGFR𝗂 
level. (A) RTK array analysis of lysates from MSCs trans-
fected with 3 μg scrambled siRNA as a control, siRNA 
PDGFRα or siRNA PDGFRβ, stimulated using 20 ng/ml 
PDGF-BB in serum-free conditions for 10 min at 37°C. Each 
array was identically exposed to detection reagents and 
ﬁ  lm. A representative example of two independent experi-
ments is shown. (B) Bar graph comparing VEGF-A165– and 
PDGF-BB–induced PDGFR tyrosine phosphorylation levels. 
Data represent VEGF-A165 and PDGF-BB–stimulated con-
trols from RTK array analysis shown in Fig. 5 B and Fig. 
6 A, respectively. Mean pixel density ± the SD of dupli-
cate spots, normalized against duplicate phosphotyrosine-
positive control spots = 100. (C) Immunoprecipitation 
(IP) analysis of PDGFR tyrosine phosphorylation levels. 
MSCs in serum-free conditions were unstimulated with 
growth factor (basal), or stimulated with either 20 ng/ml 
VEGF-A165 or PDGF-BB as a control, for 10 min at 37°C. 
PDGFRs were isolated from MSC lysates by IP analysis using 
anti-PDGFRα or anti-PDGFRβ, and then tyrosine phosphor-
ylation detected by immunoblot (IB) analysis using anti-
phosphotyrosine (Tyr-P). Membranes were reprobed with 
corresponding anti-PDGFRα or anti-PDGFRβ as loading 
controls. A representative of two independent experiments 
is shown.JCB • VOLUME 177 • NUMBER 3 • 2007  496
of PDGFRβ tyrosine phosphorylation to that demonstrated us-
ing RTK array analysis (Fig. 6, A and B), 20 ng/ml PDGF-BB 
or VEGF-A165 induced comparable levels of PDGFRα tyrosine 
phosphorylation (Fig. 6 C). Thus, both RTK array and immuno-
precipitation analyses show that VEGF-A165–induced PDGFR 
tyrosine phosphorylation levels are similar in magnitude to 
PDGF-BB–stimulated PDGFRα.
VEGF-A induced a dose-dependent increase 
in PDGFR tyrosine phosphorylation
To further examine the effects of VEGF-A on PDGFR tyrosine 
phosphorylation levels, MSCs were exposed to increasing con-
centrations of VEGF-A165 or PDGF-BB as a positive control. 
Both VEGF-A165 and PDGF-BB produced a dose-dependent 
increase in PDGFRα and PDGFRβ tyrosine phosphorylation 
levels (Fig. 7). In the case of VEGF-A165, the minimum concen-
tration required to induce a detectable increase in PDGFRα or 
PDGFRβ tyrosine phosphorylation was 10 ng/ml (Fig. S2, avail-
able at http://www.jcb.org/cgi/content/full/jcb.200608093/DC1). 
In comparison, PDGFRα and PDGFRβ were initially stimu-
lated using 5 and 2 ng/ml PDGF-BB, respectively (Fig. S2). 
Thus, the data further highlight the comparable tyrosine 
phosphorylation levels induced by PDGF-BB stimulating 
PDGFRα and by VEGF-A165 stimulating either PDGFRα or 
PDGFRβ.
VEGF-A165 did not induce PDGF-BB 
expression or release
We have previously demonstrated that MSCs do not express 
PDGF-B mRNA, and VEGF-A165 exposure did not stimulate 
  either PDGF-A, -B, -C, or -D transcript expression (Ball et al., 
2007). Furthermore, we demonstrated by ELISA that VEGF-A 
exposure did not increase the level of soluble PDGF-BB (which 
binds to both PDGFRs) in the medium (Fig. S3, available at 
http://www.jcb.org/cgi/content/full/jcb.200608093/DC1).
VEGF-A165 bound to both PDGFR𝗂 
and PDGFR𝗃
Having established by several methods that VEGF-A165–
  stimulated tyrosine phosphorylation of both PDGFRs, we went 
on to confi  rm VEGF-A165 binding to cell surface PDGFRα and 
PDGFRβ using a cross-linking approach. After VEGF-A165 
stimulation, PDGFR immunoprecipitation, and immunoblot 
analysis, a distinct association between VEGF-A and PDGFRα 
or PDGFRβ was demonstrated (Fig. 8 A). Cell surface inhibition 
of either PDGFRα or PDGFRβ using specifi  c neutralization 
Figure 7.  VEGF-A induced a dose-dependent increase in 
PDGFR tyrosine phosphorylation. The effects of varying 
VEGF-A165 concentration on induced PDGFR tyrosine 
phosphorylation levels was determined by speciﬁ  c ELISAs. 
MSCs in serum-free conditions were exposed to 0.5, 1, 2, 
5, 10, 25, 50, 100, or 200 ng/ml VEGF-A165 for 10 min 
at 37°C. As a control, cells were also exposed to identical 
concentrations of PDGF-BB. MSC lysates were assayed 
for either PDGFRα or PDGFRβ tyrosine phosphorylation 
using a corresponding ELISA. Increased tyrosine phos-
phorylation is represented by an increase in optical den-
sity (OD450nm). Data shown are mean OD450nm ± the SD 
determined from two independent experiments performed 
in triplicate.
Figure 8.  VEGF-A associated with both PDGFR𝗂 and PDGFR𝗃. Binding of 
VEGF-A to either PDGFRα or PDGFRβ was examined using a cross-linking 
approach. MSCs were unstimulated (basal) or stimulated with either 
10 ng/ml VEGF-A165 (165) or PDGF-BB (BB) as a positive control, or 10 ng/ml 
TGF-β1 as a negative control (not depicted), for 10 min at 37°C. To inhibit 
growth factor binding to the respective PDGFR, MSCs were also pretreated 
with either 10 μg/ml anti-PDGFRα (Rα) or -PDGFRβ (Rβ) cell surface neu-
tralization antibodies for 30 min at 37°C, before growth factor stimulation. 
Growth factor binding to PDGFR was captured by adding 1 mM of a cell 
membrane–impermeable cross-linking agent (DTSSP), followed by immuno-
precipitation (IP) analysis using anti-PDGFRα or anti-PDGFRβ, then growth 
factor association detected by immunoblot (IB) analysis using corre-
sponding (A) anti–VEGF-A or (B) –PDGF-B. Membranes were reprobed 
with anti-PDGFRα or -PDGFRβ as loading controls. A representative of 
three independent experiments is shown for each analysis.VEGF CAN SIGNAL THROUGH PDGF RECEPTORS • BALL ET AL. 497
  antibodies before growth factor stimulation resulted in de-
creased VEGF-A association with the corresponding PDGFR 
(Fig. 8 A), demonstrating the specificity of the interaction. 
Reprobing the membranes using anti–PDGF-B produced no 
immunoreactivity (unpublished data). Using the same approach, 
PDGF-BB (which binds both PDGFRs) stimulation as a positive 
control demonstrated that both PDGFRs associated with PDGF-
BB (Fig. 8 B). In addition, TGF-β1 stimulation used as a negative 
control, immunoprecipitated with anti-PDGFRβ, and immuno-
blotted using anti–TGF-β1 showed no detectable TGF-β1 asso-
ciation with PDGFRβ (unpublished data), further demonstrating 
the specifi  city of the analysis.
VEGF-A165 inhibited PDGF-induced 
MSC migration
To examine the potential competition between VEGF-A and 
PDGF ligands to bind PDGFRs, we performed Boyden chamber 
migration assays in the presence of varying concentration ratios 
of VEGF-A165 and PDGF-AA, which only binds to PDGFRα, or 
PDGF-BB, which binds to both PDGFRα and PDGFRβ. 10 ng/ml 
of either PDGF-AA or -BB in the lower half of a Boyden 
chamber signifi  cantly increased MSC migration above growth 
factor–independent basal levels (Fig. 9), as previously shown 
(Fig. 1 A). However, when the cell suspension in the upper half 
of a Boyden chamber was preincubated with 10 ng/ml VEGF-A165, 
MSC migration toward either 10 ng/ml PDGF-AA or -BB in the 
lower chamber was signifi  cantly inhibited (>90% and >85% 
inhibition, respectively; Fig. 9). Higher ratios of VEGF-A165/
PDGF also resulted in similar inhibition of PDGF-induced 
migration (unpublished data). Thus, VEGF-A165 attenuation of 
both PDGF-AA– and -BB–induced migration demonstrated 
VEGF-A165 inhibition of both PDGFRα and PDGFRβ, providing 
further evidence for VEGF-A binding to both PDGFRs.
Discussion
In this study, we demonstrate that VEGF-A regulates MSC 
migration and proliferation, despite the fact that RT-PCR or fl  ow 
cytometry analysis provided no evidence for VEGFR1-3 
  expression. Furthermore, using a human phospho-RTK array, 
which is more sensitive than immunoprecipitation, VEGF-A165 
resulted in no detectable VEGFR1-3 tyrosine phosphorylation. 
However, VEGF-A–induced PDGFRα and PDGFRβ tyrosine 
phosphorylation was clearly confi  rmed, highlighting that VEGF-A 
exerts its effect on MSCs by the stimulation of PDGFRs.
Using complementary approaches, we provide evidence 
of a novel VEGF-A/PDGFR signaling mechanism, showing 
that VEGF-A can signal using both PDGFRs. Heparin-binding 
domains are important modulators of VEGF subtype binding 
and biological activity, VEGF-A165 binds heparin, but VEGF-A121 
does not (Wijelath et al., 2006; Yamazaki and Morita, 2006). 
Because we demonstrated that both VEGF-A isoforms stimu-
lated MSC and HDF migration, heparin binding is unlikely to be 
an important determinant. Pretreatment of MSCs with a PDGF 
RTK inhibitor signifi  cantly reduced VEGF-A–stimulated MSC 
migration. Neutralizing either cell surface PDGFRα or PDGFRβ 
using a specifi  c blocking antibody also resulted in signifi  cant 
inhibition of VEGF-A–induced migration. Furthermore, blocking 
either PDGFRα or PDGFRβ expression using siRNA oligo-
nucleotides signifi  cantly attenuated VEGF-A–  induced migration, 
with RTK array analysis confi  rming decreased tyrosine phosphory-
lation of the respective PDGFRs. Thus, both PDGFRs are 
  essential for VEGF-A–induced migration, suggesting that both 
PDGFR homodimers (-αα and -ββ) and/or a heterodimer (-αβ) 
mediate VEGF-A/PDGFR signaling.
PDGFRα neutralization by antibody blocking or siRNA 
knockdown resulted in a greater decrease in VEGF-A–induced 
migration than corresponding PDGFRβ inhibition, which may 
refl  ect VEGF-A binding affi  nity to PDGFRα. We have previ-
ously shown that the MSCs used in this study express abundant 
PDGFRα, have a high ratio of PDGFRα to PDGFRβ, and, 
  importantly, virtually every cell coexpressed both receptors (Ball 
et al., 2007). The two PDGFRs have different PDGF binding 
 affi  nities; PDGFRβ has a higher affi  nity for PDGF-B or -D, 
whereas PDGFRα has a higher affi  nity for PDGF-A or -C 
(Betsholtz et al., 2004). PDGF-C and -D are structurally more 
Figure 9.  PDGF-induced MSC migration was inhibited by 
VEGF-A. The effects of VEGF-A on PDGF-induced MSC 
  migration was examined using Boyden chamber migra-
tion assays. MSCs were preincubated with 10 ng/ml 
VEGF-A165 for 10 min, before adding the cell suspension 
onto the upper chamber membrane surface and exposure to 
10 ng/ml PDGF-AA or -BB in the lower half of a Boyden 
chamber for 5 h. MSCs not exposed to either growth factor 
represents a growth factor–independent migration control. 
Images below each bar graph are representative of 
  migratory cells/ﬁ  eld (using a 10× objective lens) on the 
membrane underside. Data shown are the mean number 
migratory cells ± the SD determined from 10 random 
ﬁ  elds from each of two independent experiments. *, P < 
0.001 compared with the respective migration induced 
by PDGF alone.JCB • VOLUME 177 • NUMBER 3 • 2007  498
similar to VEGF-A than to PDGF-A or -B (Reigstad et al., 
2005), and both bind to a PDGFRαβ heterodimer (Fredriksson 
et al., 2004). MSCs exposed to PDGF-BB resulted in PDGFRα 
and PDGFRβ tyrosine phosphorylation levels being 2.2- and 
6.0-fold higher, respectively, than corresponding VEGF-A–
stimulated receptors. In comparison, VEGF-A induced similar 
levels of PDGFRα and PDGFRβ tyrosine phosphorylation, 
which may refl  ect a preference for PDGFRαβ stimulation. Thus, 
the data suggest that heterodimeric PDGFRαβ, at least in part, 
mediates VEGF-A/PDGFR signaling. The biological functions 
of PDGF-activated heterodimeric PDGFRαβ are not defi  ned 
(Fredriksson et al., 2004).
Interestingly, phospho-RTK array analysis revealed that 
in addition to VEGF-A165–induced PDGFRα and PDGFRβ 
tyrosine phosphorylation, VEGF-A165 stimulated EGFR, EphA7, 
and Axl tyrosine phosphorylation. PDGF-BB also stimulated 
EGFR phosphorylation, as well as FGFR3, but not EphA7 or 
Axl receptors, indicating that EphA7- and Axl-induced tyrosine 
phosphorylation were VEGF-A specifi  c. Because siRNA knock-
down of either PDGFRα or PDGFRβ had little impact on 
EphA7 or Axl tyrosine phosphorylation levels, the mechanism 
of VEGF-A–induced, ligand-independent dimerization and ac-
tivation of EphA7 and Axl receptors remains to be determined.
We demonstrated that either VEGF-A165 or -A121 isoforms 
were able to induce MSC and HDF migration, and that both cell 
types expressed NP-1 and -2 transmembrane glycoproteins. 
Although VEGF-A165 binds to NP-1 and -2, VEGF-A121 binds to 
neither (Gluzman-Poltorak et al., 2000). NPs are not known to 
signal independently after VEGF binding, but are proposed to act 
as coreceptors and facilitate binding of certain VEGF subtypes 
to VEGFRs (Neufeld et al., 2002). Thus, although we cannot 
discount a role for NPs, in the absence of VEGFRs, to facilitate 
VEGF-A165 binding to PDGFRs, NPs are unlikely to be involved in 
mediating VEGF-A121–induced chemotactic or mitogenic effects.
Along with fi  nding that VEGF-A165 was able to induce 
MSC migration, we also demonstrated that a low concentration 
of VEGF-A165 at the cell surface can inhibit both PDGF-AA– 
and -BB–mediated chemotaxis, indicating that VEGFA165 com-
petes with PDGF ligands for PDGFR occupancy. Because both 
MSCs and HDFs were shown to express abundant VEGF-A 
transcript, it is tempting to speculate that autocrine expression 
of VEGF-A may act to regulate PDGF-induced chemotaxis in 
these cell types.
The demonstration that, in the absence of VEGFRs, VEGF 
can use PDGFR-mediated signaling in both MSCs and HDFs, 
suggests the intriguing possibility that under certain circum-
stances, VEGF may have an impact on a wider range of target 
cells than previously recognized.
VEGF-A is a crucial factor in promoting the recruitment 
and proliferation of vascular cells during both physiological and 
pathological angiogenesis and neovascularization (Pierce et al., 
1995; Carmeliet and Jain, 2000). The local oxygen concentra-
tion controls the expression of VEGF, which is mediated, at 
least in part, by the transcription factor, hypoxia-inducible fac-
tor 1 (Forsythe et al., 1996). Therefore, in pathological hypoxic 
microenvironments, such as tumorigenesis (Carmeliet and Jain, 
2000), disease progression is often associated with increased 
VEGF-A and vascular remodeling. MSCs are actively recruited 
during tumor neovascularization (Annabi et al., 2003; Aghi and 
Chiocca, 2005) and engraft into established tumor lesions 
(Hung et al., 2005), forming the basis for novel therapeutic ap-
proaches. Thus, VEGF-A/PDGFR signaling, especially during 
tissue hypoxia, is likely to be an important determinant in 
the recruitment and proliferation of MSCs and other PDGFR-
positive cells.
Materials and methods
Cell culture
Human MSCs from normal bone marrow of 20- and 26-yr-old females and 
18-, 22-, and 24-yr-old males (Cambrex), HUVECs from 35- and 29-yr-old 
females, and a pooled batch of HUVECs and HDFs from 23- and 32-yr-old 
males (Cascade Biologics) were maintained as previously described (Ball 
et al., 2004). MSCs were analyzed at passage 4, whereas HUVECs and 
HDFs were analyzed at passage 6. All were grown in serum-free medium 
for 24 h before analysis. The MSCs used in this study express a wide range 
of smooth muscle cell markers, including the smooth muscle cell–selective 
marker smoothelin-B (Ball et al., 2004), and can also differentiate into 
osteoblast, chondrocyte, and adipocyte lineages (McBeath et al., 2004). 
They are positive for CD29, CD44, CD105, and CD166, but negative for 
hematopoietic cell markers CD14, CD34, and CD45. We have also dem-
onstrated that they are negative for the speciﬁ   c pericyte marker 3G5 
(Nayak et al., 1988; Ball et al., 2007).
Growth factors and inhibitors
All growth factors, PDGF-AA (221-AA), PDGF-BB (220-BB), TGF-β1 (240-B), 
VEGF-A165 (293-VE), and VEGF-A121 (298-VS), were obtained from 
R&D Systems. Three different batches of VEGF-A165 were used during this 
study, all containing BSA carrier protein (50 μg BSA/1 μg cytokine). We 
excluded the possibility that the VEGF-A may contain contaminant PDGF-
BB (which binds to both PDGFRs). Immunoblot analysis (using anti–PDGF-B) 
readily detected 1 ng PDGF-B, but 100 ng VEGF-A165 produced no PDGF-B 
immunoreactivity, indicating that any potential PDGF-BB contamination 
must be <1 ng (Fig. S2). However, the minimum concentration of PDGF-BB 
that induced a detectable PDGFRα or PDGFRβ tyrosine phosphorylation 
response was ≥5 ng and 2 ng, respectively (Fig. S2). Thus, any potential 
contamination of <1 ng PDGF-BB (in 100 ng VEGF-A165) would not induce 
a detectable PDGFR tyrosine phosphorylation response.
In addition, VEGF-A165 from two different suppliers (Invitrogen and 
Autogen Bioclear) was also tested, and both showed similar biological 
effects to the VEGF-A165 obtained from R&D Systems.
Anti–human PDGFRα (MAB322) and PDGFRβ (AF385) antibodies 
were used to speciﬁ   cally neutralize PDGFRs, whereas anti–human 
VEGFR1 (AF321) and VEGFR2 (MAB3572) antibodies were used to spe-
ciﬁ  cally neutralize VEGFR1 and VEGFR2 (R&D Systems). PDGFR tyrosine 
kinase was inhibited using PDGFR tyrosine kinase inhibitor III (50 nM 
PDGFRα IC50; PDGFRβ IC50, 80 nM with IC50 ≥ 30 μM for EGFR, FGFR, 
Src, PKA, and PKC; Matsuno et al., 2002; Calbiochem). VEGFR2 tyro-
sine kinase was inhibited using VEGFR2 inhibitor V (IC50 < 2 nM with 
IC50 > 50 μM for VEGFR1, EGFR, FGFR1 and PDGFRβ; Endo et al., 
2003; Calbiochem).
Semiquantitative RT-PCR
Semiquantitative RT-PCR was performed as previously described (Ball 
et al., 2004). Each primer pair was designed using the same parameters, 
resulting in similar Tm values (58.8–60.0) and product lengths as shown. 
VEGFR-1 (99-bp), forward (5′-G  C  G  A  C  G  T  G  T  G  G  T  C  T  T  A  C  G  -3′) and reverse 
(5′-G  G  C  G  A  C  T  G  C  A  A  A  A  G  T  C  C  T  -3′); VEGFR-2 (81-bp), forward (5′-C  A  T  C-
C  A  G  T  G  G  G  C  T  G  A  T  G  A  -3′) and reverse (5′-T  G  C  C  A  C  T  T  C  C  A  A  A  A  G  C  A  A  -3′); 
VEGFR-3 (87-bp), forward (5′-G  A  T  G  C  G  G  G  A  C  C  G  T  A  T  C  T  G  -3′) and reverse 
(5′-A  T  C  C  T  C  G  G  A  G  C  C  T  T  C  C  A  C  -3′); VEGF-A (98-bp), forward (5′-C  A  C  C  C-
A  T  G  G  C  A  G  A  A  G  G  A  G  -3′) and reverse (5′-C  A  C  C  A  G  G  G  T  C  T  C  G  A  T  T  G  G  -3′); 
NP-1 (77-bp), forward (5′-G  C  A  G  T  G  G  C  T  C  C  T  G  G  A  A  G  A  -3′) and reverse 
(5′-A  G  T  C  G  C  C  T  G  C  A  T  C  C  T  G  T  C  -3′); NP-2 (83-bp), forward (5′-A  T  T  C  G  G  G-
A  T  G  G  G  G  A  C  A  G  T  -3′) and reverse (5′-C  C  C  G  A  G  G  A  G  A  T  G  A  T  G  G  T  G  -3′); 
and GAPDH (71-bp), forward (5′-A  A  G  G  G  C  A  T  C  C  T  G  G  G  C  T  A  C  -3′) and re-
verse (5′-G  T  G  G  A  G  G  A  G  T  G  G  G  T  G  T  C  G  -3′). An additional pair of primers 
for all three VEGFRs (VEGFR1-3) that was designed to different   sequence 
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Flow cytometry
For single-color ﬂ  ow cytometry, MSCs, HUVECs, or HDFs (4×10
6 cells/ml) 
were incubated with either PE-conjugated anti–human VEGFR1-PE 
(FAB321P), VEGFR2-PE (FAB357P), or VEGFR3-PE (FAB3492P) antibodies, 
or control anti–IgG1-PE antibody (IC002P; R&D Systems). VEGFR1 
(MAB4711), VEGFR2 (MAB3572), VEGFR3 (MAB3491) antibodies, or 
control anti-IgG1 (MAB002) antibody (R&D Systems) were also used after 
secondary labeling with a FITC secondary antibody (Dako Cytomation). 
HDFs were also incubated with either anti–human PDGFRα-PE (sc-21789PE) 
or PDGFRβ-PE (sc-19995PE) antibodies (Santa Cruz Biotechnology). For 
each sample, 100,000 cells were counted using a FACscan cytometer 
(Becton Dickinson) at a ﬂ  ow rate of <200 events/s.
Migration assay
Cell migration was determined using a modiﬁ   ed Boyden chamber 
assay. Cell culture ﬁ  lter inserts of 8 μm pore size, 6.5 mm diam (Becton 
Dickinson), were coated on the underside with 10 μg/ml ﬁ  bronectin in 
PBS, overnight at 4°C. MSCs (1×10
5) were added to the upper cham-
ber with 10 or 20 ng/ml growth factors in the lower chamber and cells 
allowed to migrate to the membrane underside for 5 h at 37°C in a 
humidiﬁ  ed atmosphere of 5% CO2 in air. In some experiments, cells were 
preincubated with receptor neutralization antibodies or kinase inhibitors 
(10  μg/ml anti-VEGFR1 or anti-VEGFR2 neutralization antibodies, 
100 nM VEGFR2 tyrosine kinase inhibitor [VEGFR2-TK], 2 μM PDGFR 
tyrosine kinase inhibitor [PDGFR-TK], and 10 μg/ml anti-PDGFRα or 
-PDGFRβ neutralization antibodies) for 30 min at 37°C before growth 
factor exposure. After migration, cells on the upper membrane surface 
were removed and migratory cells on the membrane underside were 
ﬁ  xed using 5% (wt/vol) glutaraldehyde and stained using 0.1% (wt/vol) 
crystal violet solution. Filter inserts were inverted and the number of 
migratory cells on the membrane underside (cells/ﬁ  eld using a 10× NA 
0.3 Olympus UPlanF1 objective lens) was determined, at room tempera-
ture, by visualizing the crystal violet–stained cells directly on insert under-
sides by phase-contrast microscopy, without use of ﬂ  uorochromes (BX51; 
Olympus). Images were captured using a computerized imaging system 
(MetaMorph imaging v 5.0; Molecular Devices) and CoolSNAP (Photo-
metrics) camera system.
Proliferation assay
MSCs (2,000 cells/well) in growth medium were seeded in 96-well plates 
and incubated with 10 ng/ml growth factors at 37°C in a humidiﬁ  ed atmo-
sphere of 5% CO2 in air. Experiments were also conducted using MSCs 
pretreated with 10 μg/ml receptor neutralization antibodies for 30 min 
before growth factor addition. At the end of each time point, a CyQuant 
cell proliferation assay kit (Invitrogen) was used to detect MSC prolifera-
tion. Cells were treated in situ according to the manufacturer’s protocol. To 
generate a standard curve, a serial dilution of MSCs (2,000–20,000) 
were also aliquoted into separate wells and treated the same as sample 
cells. Plates were read using a scanning multiwell ﬂ  uorometer at a wave-
length of 480 nm, and cell numbers were calculated using the standard 
curve for each plate.
RTK array analysis
A human Phospho-RTK Array kit (R&D Systems), which has a greater sen-
sitivity than immunoprecipitation analysis, was used to simultaneously 
detect the relative tyrosine phosphorylation levels of 42 different RTKs in 
untreated or growth factor–treated MSC lysates. Each array contains 
duplicate validated control and capture antibodies for speciﬁ  c RTKs. MSCs 
cultured for 24 h in serum-free medium were stimulated with 20 ng/ml 
growth factors for 10 min at 37°C in a humidiﬁ  ed atmosphere of 5% CO2 
in air, and then immediately placed on ice, washed twice with chilled 
PBS, and isolated using chilled lysis buffer (20 mM Tris-HCl, pH 8.0, 150 
mM NaCl, 1% NP-40, 2.5 mM EDTA, 1 mM sodium orthovanadate, 10% 
glycerol, 10 μg/ml aprotinin, 10 μg/ml leupeptin, and 1 mM phenyl-
methylsulfonyl ﬂ  uoride). Total protein concentration was quantitated using 
a BCA assay kit (Pierce Chemical Co.). RTK array analysis was performed 
according to the manufacturer’s protocol. In brief, array membranes were 
blocked, incubated with 500 μg MSC lysate overnight at 4°C, washed, 
and incubated with anti–phosphotyrosine-HRP for 2 h at room tempera-
ture, washed again, and developed with ECL Western blotting detection 
reagent (GE Healthcare), and RTK spots were visualized using Kodak 
XAR ﬁ  lm. Average pixel density of duplicate spots were determined by 
Gene Tools v3 software (Syngene), with values normalized against corner 
duplicate phosphotyrosine-positive control spots, which were assigned a 
value of 100.
siRNA transfection
MSCs (5×10
5 cells), together with 3-μg siRNAs, were transfected by electro-
poration using a human Nucleofector kit (Amaxa) and cultured overnight 
in growth medium. Validated siRNAs, which were functionally tested to 
provide  ≥70% target gene knockdown, were used for PDGFRα and 
PDGFRβ knockdown and a scrambled siRNA control (QIAGEN).
Phosphorylated PDGFR immunoprecipitation and sandwich ELISAs
Cells were isolated using ice-cold lysis buffer and 100 μg lysates pre-
cleared using 10% (wt/vol) protein A–Sepharose (GE Healthcare), and 
then incubated with monoclonal anti–human PDGFRα (MAB1264) or 
PDGFRβ (MAB1263; R&D Systems) overnight at 4°C. Immune complexes 
were isolated by incubation with 10% (wt/vol) protein A–Sepharose for 
2 h. Immunoblot analysis was performed as previously described (Ball 
et al., 2004), using a monoclonal anti–human antibody for phosphoryl-
ated tyrosine (PY99; sc-7020; Santa Cruz Biotechnology). Human phospho-
PDGFRα, phospho-PDGFRβ and soluble PDGF-BB levels were all detected 
by ELISA kits, performed according to the manufacturer’s protocol 
(R&D Systems).
Cross-linking analysis of growth factor association with PDGFRs
After stimulation of MSCs in serum-free conditions with growth factor, 
1 mM 3, 3′-Dithiobis[sulfosuccinimidyl propionate] (DTSSP; Pierce Chemical 
Co.) was directly added to the medium and incubated for 30 min at room 
temperature, and the cross-linking reaction was quenched using 20 mM 
Tris, pH 7.5, for 15 min at room temperature. DTSSP is a membrane-
impermeable thiol-cleavable reagent that is used for cross-linking molecules 
at the cell surface. PDGFRs were immunoprecipitated from cell lysates using 
anti–human PDGFRα (MAB1264) or PDGFRβ (MAB1263; R&D Systems). 
Proteins conjugated to PDGFR–DTSSP complexes were dissociated by add-
ing 5% β-mercaptoethanol and boiling for 5 min. Growth factors associ-
ated with PDGFRs were resolved by SDS-PAGE and detected by immunoblot 
analysis, as previously described (Ball et al., 2004), using the following 
corresponding monoclonal anti–human antibodies: VEGF-A (MAB293), 
PDGF-B (MAB220), or TGF-β1 (MAB240; R&D Systems).
Statistical analysis
In all quantitation experiments, results are expressed as the mean ± the SD. 
Statistical differences between sets of data were determined by using a paired 
t test on SigmaPlot 8.0 software, with P < 0.05 considered signiﬁ  cant.
Online supplemental material
Fig. S1 shows that inhibition of PDGFRα or PDGFRβ attenuated VEGF-A–
  induced MSC proliferation. Fig. S2 shows that VEGF-A contained no 
detectable PDGF-BB contamination. Fig. S3 shows that VEGF-A did not 
change soluble PDGF-BB levels.
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